tldrdailynews.com logo

"Eli Lilly Projects 20% Sales Boost from Diabetes and Obesity Drugs, Surges Toward Record Stock High"

1 min read
Source: Financial Times
TL;DR

Eli Lilly projects a 20% increase in sales this year, attributing the growth to the strong performance of its diabetes and obesity drugs. The pharmaceutical company anticipates significant revenue from these medications, reflecting the ongoing demand for treatments in these therapeutic areas.

Topics:top-newsbusiness#business#diabetes-drugs#eli-lilly#obesity-drugs#pharmaceutical-industry#sales-boost
Share this article
  1. Live news: Eli Lilly says diabetes and obesity drugs will boost sales by 20% this year  Financial Times
  2. Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue  CNBC
  3. Lilly expects strong 2024 profit on rising demand for weight-loss drug  Yahoo Finance
  4. Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlook  MarketWatch
  5. Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance | Eli Lilly and Company  Investors | Eli Lilly and Company

Want the full story? Read the original reporting

Read on Financial Times